BSE · 543828
Sudarshan Pharma Industries Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹200 Cr with net profit ₹10 Cr — a 4.77% net margin, versus 2.72% the period before.
Shareholding
As of 2026-06-30
- Promoter58.93%
- Public21.69%
- FII19.38%
1,231 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.31× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Trading · ranked #53 of 666 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,96,659 Cr | 24.35 | 4.87 | 3.42% | 9.3% |
| Avenue Supermarts Limited | ₹2,52,648 Cr | 383.94 | 10.32 | 12.14% | 4.32% |
| Trent Ltd. | ₹1,59,927 Cr | 92.65 | 22.9 | 24.62% | 8.57% |
| FSN E-Commerce Ventures Ltd. | ₹95,580 Cr | 1236.11 | 66.46 | 13.87% | 1.99% |
| Vishal Mega Mart Limited | ₹50,539 Cr | 56.78 | 6.81 | 11.32% | 6.61% |
| Premier Energies Limited | ₹44,610 Cr | 29.55 | 10.36 | 35.05% | 19.3% |
| Aegis Logistics Limited | ₹43,850 Cr | 106.87 | 7.24 | 14.83% | 10.78% |
| Aditya Infotech Limited | ₹38,417 Cr | 226.85 | 20.46 | 19.61% | 8.72% |
| Redington Limited | ₹24,309 Cr | 15.27 | 2.39 | 14.67% | 1.25% |
| Honasa Consumer Limited | ₹14,510 Cr | 209.37 | 10.28 | 14.16% | 8.36% |
| Sudarshan Pharma Industries Ltd.(this company) | ₹924 Cr | 39.59 | 5.96 | 15.03% | 3.32% |
AI analysis
AI-generated · google/gemini-2.5-flashSudarshan Pharma Industries Ltd. is listed with a market capitalization of Rs 1011 Cr. The company reported revenue of Rs 507.57 Cr and a profit margin of 331.6%.
Positives
- +The company reported a high profit margin of 331.6%.
- +Return on Equity (ROE) is 15.03%.
- +Promoter holding of 57.3898% as of March 31, 2026, indicates significant insider ownership and has remained consistent over the last several quarters.
- +No promoter shares are reported as pledged.
Negatives
- −The debt-to-equity ratio is 1.13, indicating elevated leverage.
- −The company is under ESM surveillance (ESM 1).
- −No annual revenue growth figure is provided in the supplied data.
- −No EPS figures are provided for quarterly results.
Financial Performance
The company recorded annual revenue of Rs 507.57 Cr in Mar 2025. Quarterly revenues have varied, with Rs 199.81 Cr in Mar 2026 and Rs 158.37 Cr in Dec 2025. Annual net profit was Rs 15.96 Cr in Mar 2025. Quarterly net profit reached Rs 10.73 Cr in Mar 2026.
Profitability & Returns
Sudarshan Pharma Industries Ltd. showed a profit margin of 331.6%. The Return on Equity (ROE) stands at 15.03% and Return on Capital Employed (ROCE) is 12.76%. The company's EPS was Rs 0.97.
Balance Sheet
The company has a debt-to-equity ratio of 1.13, indicating its reliance on debt financing. The book value per share is Rs 6.44.
Ownership & Pledges
There are no promoter pledges reported.
Regulatory & Surveillance
Sudarshan Pharma Industries Ltd. is currently under ESM surveillance (ESM 1).
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Sudarshan Pharma Industries Ltd.share price & fundamentals